Molecular neuroscience at its "high": bibliometric analysis of the most cited papers on endocannabinoid system, cannabis and cannabinoids.
Bibliometrics
Cannabis
Citation analysis
Endocannabinoid
Molecular neuroscience
VOSviewer
Journal
Journal of cannabis research
ISSN: 2522-5782
Titre abrégé: J Cannabis Res
Pays: England
ID NLM: 101752723
Informations de publication
Date de publication:
07 Jun 2019
07 Jun 2019
Historique:
received:
23
12
2018
accepted:
11
04
2019
entrez:
2
2
2021
pubmed:
7
6
2019
medline:
7
6
2019
Statut:
epublish
Résumé
Cannabis, cannabinoids and endocannabinoids are heavily investigated topics with many articles published every year. We aimed to identify the 100 most cited manuscripts among the vast literature and analyze their contents. Web of Science (WoS) Core Collection was searched to identify the 100 most cited relevant manuscripts, which were analyzed with reference to (1) authorship, (2) institution, (3) country, (4) document type, (5) journal, (6) publication year, (7) WoS category, and (8) citation count. Semantic content and citation data of the manuscripts were analyzed with VOSviewer. The most cited manuscripts were published between 1986 and 2016, with the majority being published in the 2000s (n = 51). The number of citations for the top 100 articles ranged from 469 to 3651, with a median citation count of 635.5. The most prolific authors were Vincenzo Di Marzo (n = 11) and Daniele Piomelli (n = 11). The major contributing countries were USA (n = 49), Italy (n = 22), UK (n = 19), and France (n = 11). The most prolific institutions were University of California (n = 14), National Research Council of Italy (n = 12) and National Institutes of Health USA (n = 12). The manuscripts consisted of original articles (n = 75), reviews (n = 24) and a note (n = 1). The most dominant journal was Nature (n = 15). The major WoS categories associated were Multidisciplinary sciences (n = 31), Neurosciences (n = 20), Pharmacology / Pharmacy (n = 16), and General / Internal Medicine (n = 11). The top-ranked manuscripts among the 100 were concerning analgesia, weight loss, long-term potentiation, depolarization-induced suppression of inhibition, opiates and other topics. Cannabinoid type 1 (CB1) receptor was studied by more of the top 100 papers in comparison to cannabinoid type 2 (CB2) receptor. The most frequently mentioned chemicals in these publications were 2-arachidonoylglycerol, tetrahydrocannabinol, and anandamide. Together, these manuscripts comprise the most highly cited publications in the topic, literally the molecular neuroscience at its "high".
Sections du résumé
BACKGROUND
BACKGROUND
Cannabis, cannabinoids and endocannabinoids are heavily investigated topics with many articles published every year. We aimed to identify the 100 most cited manuscripts among the vast literature and analyze their contents.
METHODS
METHODS
Web of Science (WoS) Core Collection was searched to identify the 100 most cited relevant manuscripts, which were analyzed with reference to (1) authorship, (2) institution, (3) country, (4) document type, (5) journal, (6) publication year, (7) WoS category, and (8) citation count. Semantic content and citation data of the manuscripts were analyzed with VOSviewer.
RESULTS
RESULTS
The most cited manuscripts were published between 1986 and 2016, with the majority being published in the 2000s (n = 51). The number of citations for the top 100 articles ranged from 469 to 3651, with a median citation count of 635.5. The most prolific authors were Vincenzo Di Marzo (n = 11) and Daniele Piomelli (n = 11). The major contributing countries were USA (n = 49), Italy (n = 22), UK (n = 19), and France (n = 11). The most prolific institutions were University of California (n = 14), National Research Council of Italy (n = 12) and National Institutes of Health USA (n = 12). The manuscripts consisted of original articles (n = 75), reviews (n = 24) and a note (n = 1). The most dominant journal was Nature (n = 15). The major WoS categories associated were Multidisciplinary sciences (n = 31), Neurosciences (n = 20), Pharmacology / Pharmacy (n = 16), and General / Internal Medicine (n = 11).
CONCLUSIONS
CONCLUSIONS
The top-ranked manuscripts among the 100 were concerning analgesia, weight loss, long-term potentiation, depolarization-induced suppression of inhibition, opiates and other topics. Cannabinoid type 1 (CB1) receptor was studied by more of the top 100 papers in comparison to cannabinoid type 2 (CB2) receptor. The most frequently mentioned chemicals in these publications were 2-arachidonoylglycerol, tetrahydrocannabinol, and anandamide. Together, these manuscripts comprise the most highly cited publications in the topic, literally the molecular neuroscience at its "high".
Identifiants
pubmed: 33526099
doi: 10.1186/s42238-019-0004-y
pii: 10.1186/s42238-019-0004-y
pmc: PMC7815052
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4Références
N Engl J Med. 1989 Mar 23;320(12):762-8
pubmed: 2784193
Nature. 1993 Jan 7;361(6407):31-9
pubmed: 8421494
Bioorg Med Chem. 2015 Apr 1;23(7):1377-85
pubmed: 25703248
Food Chem. 2018 Dec 15;269:455-465
pubmed: 30100460
Prog Lipid Res. 2011 Apr;50(2):193-211
pubmed: 21295074
Popul Health Manag. 2019 Aug;22(4):362-368
pubmed: 30300079
J Nat Prod. 2016 Feb 26;79(2):324-31
pubmed: 26836472
J Pain Res. 2017 May 02;10:989-998
pubmed: 28496355
Eur J Endocrinol. 2017 Jun;176(6):R309-R324
pubmed: 28246151
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3662-5
pubmed: 11259648
J Alzheimers Dis. 2015;43(3):977-91
pubmed: 25125475
J Pharmacol Exp Ther. 2002 Jun;301(3):1020-4
pubmed: 12023533
Eur J Neurosci. 2004 Aug;20(3):859-63
pubmed: 15255998
Brain Res Mol Brain Res. 1999 Feb 5;64(2):193-8
pubmed: 9931487
Front Pharmacol. 2018 Mar 15;9:215
pubmed: 29599720
N Engl J Med. 1979 Jun 7;300(23):1295-7
pubmed: 375088
Nat Chem Biol. 2009 Jan;5(1):37-44
pubmed: 19029917
Pain. 2012 Oct;153(10):2073-2082
pubmed: 22921260
Biochem J. 2000 Nov 1;351 Pt 3:817-24
pubmed: 11042139
Psychol Med. 2006 Oct;36(10):1447-60
pubmed: 16854249
Lancet. 2007 Nov 17;370(9600):1706-13
pubmed: 18022033
Br J Pharmacol. 2007 Dec;152(7):1092-101
pubmed: 17876302
Pharmacol Rev. 2006 Sep;58(3):389-462
pubmed: 16968947
Nature. 1997 Aug 21;388(6644):773-8
pubmed: 9285589
Front Hum Neurosci. 2018 Aug 27;12:337
pubmed: 30210323
J Neurosci. 2007 Jan 24;27(4):832-9
pubmed: 17251423
Scientometrics. 2010 Aug;84(2):523-538
pubmed: 20585380
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
Handb Exp Pharmacol. 2015;231:1-37
pubmed: 26408156
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
Br J Pharmacol. 2011 Aug;163(7):1344-64
pubmed: 21749363
Neuron. 2001 Mar;29(3):729-38
pubmed: 11301031
Front Psychol. 2017 Jul 11;8:1160
pubmed: 28744246
Nat Rev Neurosci. 2003 Nov;4(11):873-84
pubmed: 14595399
Nature. 2001 Mar 29;410(6828):588-92
pubmed: 11279497
Addict Biol. 2008 Jun;13(2):143-6
pubmed: 18482429
Front Neurosci. 2017 Mar 21;11:120
pubmed: 28377687
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3376-80
pubmed: 7724569
Int J Obes (Lond). 2006 Apr;30 Suppl 1:S13-8
pubmed: 16570099
Neuron. 2001 Mar;29(3):717-27
pubmed: 11301030
Crit Rev Oncog. 2018;23(5-6):347-370
pubmed: 30311565
Nature. 2001 Apr 12;410(6830):822-5
pubmed: 11298451
Nature. 2002 Aug 1;418(6897):530-4
pubmed: 12152079
Front Hum Neurosci. 2017 Sep 20;11:468
pubmed: 28979201
Med Hypotheses. 2006;66(2):234-46
pubmed: 16209908
JAMA. 2018 Sep 25;320(12):1227-1229
pubmed: 30193358
Br J Psychiatry. 2001 Feb;178:101-6
pubmed: 11157422
Lancet. 2005 Apr 16-22;365(9468):1389-97
pubmed: 15836887
FASEB J. 2009 Jan;23(1):183-93
pubmed: 18757503
Nature. 1990 Aug 9;346(6284):561-4
pubmed: 2165569